Wayne State University
Anna B. Moszczynska Ph.D.

Anna B. Moszczynska Ph.D.

Associate Professor, Pharmaceutical Sciences

Contact

313-577-1257
amosz@wayne.edu

Office location

EACPHS, Room 3142

Appointments

Associate Professor, Department of Pharmaceutical Sciences

Degrees and Certifications

1987 B.Sc. in Chemical Engineering, Institute of Technical Biochemistry, Technical University of Lodz, Poland

1988 M.Sc. in Chemical Engineering, Institute of Technical Biochemistry, with Honours,Technical University of Lodz, Poland

1995 M.Sc. in Cell Biology, Department of Anatomy and Cell Biology, University of Toronto, ON, Canada


2002 Ph.D. in Neurochemistry, Institute of Medical Science, University of Toronto, ON, Canada


2005 Post-doctoral Fellowship in Molecular Neurobiology, Center for Addiction and Mental Health, Toronto, ON, Canada


2007 Post-doctoral Fellowship in Molecular Genetics, University of Guelph, ON, Canada
2008 Post-doctoral Fellowship in Pharmacology, Boston University, Boston, MA, USA

 

Positions and Employment

2016 - Associate Professor. Department of Pharmaceutical Sciences, Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA. Research: The ubiquitin proteasome system in methamphetamine neurotoxicity.

2010 - Assistant Professor. Department of Pharmaceutical Sciences, Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA. Research: The ubiquitin proteasome system in methamphetamine neurotoxicity.
2008 - 2010 Research Assistant Professor. Department of Neurosciences, University of Toledo College of Medicine, Toledo, OH, USA. Research: The ubiquitin proteasome system in methamphetamine neurotoxicity.
2007 - 2008 Postdoctoral Research Associate. Laboratory of Neurochemistry, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston University School of Medicine, Boston, MA, USA. Research: The role of ubiquitination in methamphetamine neurotoxicity.
2006 - 2007 Postdoctoral Research Associate. Laboratory of Population Genetics, Department of Integrative Biology, University of Guelph and Canadian Centre for DNA Barcoding, Biodiversity Institute of Ontario, Guelph, ON, Canada. Research: DNA barcoding of the phylum, Platyhelminthes and characterization and population genetics of a transposable element, Pokey, in Daphnia.
2002 - 2005 Postdoctoral Research Fellow. Molecular Neurobiology Laboratory, Department of Neuroscience Research, Centre for Addiction and Mental Health, Toronto, ON, Canada. Research: Protein-protein interactions, transporter and receptor pharmacology, and intracellular signalling in neurodegenerative diseases.
1996 - 2002 Ph.D. student (supervisor: Dr. Stephen J. Kish). Human Neurochemical Pathology Laboratory, Department of Neuroscience Research, Centre for Addiction and Mental Health, Toronto, ON, Canada. Thesis title: Major antioxidant systems in brain of chronic methamphetamine users and in parallel animal model.
1995 - 1996 Research Associate III. Human Neurochemical Pathology Laboratory, Department of Neuroscience Research,Centre for Addiction and Mental Health, Toronto, ON, Canada. Research: Phospholipid metabolism in neurodegenerative diseases.
1992 - 1995 Master student (supervisor: Dr. Michal Opas). Department of Anatomy and Cell Biology, University of Toronto, Toronto, ON, Canada. Thesis title: Adhesion, growth and differentiation of RPE-J cell line.
1991 - 1992 Research Associate II. Department of Anatomy and Cell Biology, University of Toronto, Toronto, ON, Canada. Research: Adhesion of retinal pigment epithelial cells from chick embryos.

Awards and Honors

Technical University of Lodz Dean's Award (1987 - 1988)

University of Toronto Open Fellowship (1993 - 1994)
Ontario Graduate Scholarship (1994 - 1995)
Ontario Mental Health Foundation Scholarship (1996 - 1999)
Ontario Graduate Scholarship (1999 - 2001)
Ontario Mental Health Foundation Postdoctoral Fellowship (2003 - 2004)
Parkinson Society Canada Postdoctoral Fellowship (2004 - 2006)
NIDA K99-R00 Pathway to Independence Award (2008 - 2013)
Nomination for Abstract Presentation at NIDA's satellite mini-convention "Frontiers in Addiction Research" at the 38th Annual Meeting of the Society for Neuroscience, Washington, DC (2008)
University Research Grant (2013 - 2014)
FRAP Young Investigator Award (2013 - 2014)
University Research Grants (2013 - 2014)
Tuition Incentive Award (2015 - 2016)
Academy of Scholars WSU Junior Faculty Award (2015)

Grant support
NIH/NIDA R00 DA023085 (2010-2013) "The Role of Ubiquitination in Methamphetamine Neurotoxicity". The goal of this project was to determine whether and by what molecular mechanisms ubiquitin E3 ligase parkin protects dopaminergic terminals from methamphetamine neurotoxicity. Role: PI

NIH/NIDA R01 DA034783 (2013-2018) "Proteasome and parkin as drug targets agains methamphetamine toxicity". The goal of this project is to determine whether ubiquitin E3 ligase parkin and proteasome can promote survival and recovery from methamphetamine neurotoxicity". Role: PI

Professional Memberships

1995 Member, Society for Neuroscience (SfN)

1995 Member, International Brain Organization (IBRO)

2010 Member, American Society for Pharmacology and Experimental Therapeutics (ASPET)

2010 Member, American Association of Colleges of Pharmacy (AACP)

2011 Member, International Society for Neurochemistry (ISN)

2011 Member, New York Academy of Sciences (NYAS)

2011 Member, The Rho Chi Society

2013 Member, Society for Neuroscience Michigan Chapter (MiSfN)

2013 Member, American Association for the Advancement of Science (AAAS)

Primary Research Interest

My research interests are in the field of methamphetamine (METH) neurotoxicity. METH is a widely abused psychostimulant with a high potential for addiction. Its abuse is a substantial problem in the western US and continues to spread to other areas of the country. When taken at high doses, METH has toxic effects on brain dopaminergic and serotonergic systems in experimental animals and humans. Very high doses of the drug cause agitation, confusion, irritability, violent behavior, and impairment of psychomotor and cognitive skills, auditory hallucinations, paranoia, and formication. Despite years of research on METH neurotoxicity, no treatments currently exist to prevent, inhibit, or reverse the toxic effects of METH on the brain.

The primary research in my lab involves several projects with ubiquitin-protein E3 ligase parkin as a main protein of interest. We have recently demonstrated that binge METH decreases the function of parkin and 26S proteasome in rat striatal terminals, shortly after the last injection of the drug (J. Neurochem. 116:1005-1017, 2011) and that overexpression of parkin in nigrostriatal dopamine system partially protects dopaminergic terminals from toxicity of binge METH (Exp. Neurol. 247:359-372, 2013). Currently, my lab investigates the consequences of METH-induced parkin deficit at key points of action of the drug, i.e. mitochondria, dopamine D2 receptor (D2R), dopamine transporter (DAT) and synaptic vesicular monoamine transporter 2 (VMAT2). Our lab also studies parkin deficit-induced protein aggregation after high doses of METH. Targets for pharmaceutical manipulations are parkin, proteasome, and proteins characteristic for the dopaminergic system such as DAT and DA receptors as well as protein-protein interactions between them. The manipulations currently involve breaking unwanted protein-protein interactions using systemic injections of TAT-bound peptides.

Animal models and laboratory techniques: Wild-type, parkin knock-out (Sage Labs) and parkin overexpressing rats (generated in my laboratory), cell culture, postmortem human brains from METH users, analysis of protein-protein interactions, breaking protein-protein interactions in vivo using TAT-peptides, confocal & stereology microscopy, stereotaxic surgery, and standard lab techniques.

Positions available: postdoctoral fellow, research assistant/associate, technician

Recent Publications

1. Moszczynska, A. and Opas, M. (1994). Regulation of adhesion-related protein tyrosine kinases during in vitro differentiation of retinal pigment epithelial cells: Translocation of pp60c-src to the nucleus is accompanied by downregulation of pp125FAK. Biochem. Cell Biol. 72, 43-48. Impact factor: 2.92. Citations: 12.

Role: Experimental design, data collection and data analysis, help with preparation of the first draft of the manuscript.

2. Moszczynska, A. and Opas, M. (1994). Involvement of non-receptor protein tyrosine kinases in expression of differentiated phenotype by cells of retinal origin. Int. J. Dev. Biol. 38, 1-12. Impact factor: 2.86. Citations: 2.

Role: Experimental design, data collection and data analysis.

3. Zhou, Y., Moszczynska, A. and Opas, M. (1994). Generation and characterization of antibodies to adhesion-related molecules of retinal pigment epithelial cells. Exp. Eye Res. 58, 585-593. Impact factor: 3.02. Citations: 2.

Role: Help with data collection and data analysis.

4. Ross, B. M., Moszczynska, A., Kalasinsky, K. and Kish, S.J. (1996). Phospholipase A2 activity is selectively decreased in the striatum of chronic cocaine users. J. Neurochem. 67, 2620-2623. Impact factor: 4.24. Citations: 19.

Role: Help with data collection and data analysis.

5. Ross, B. M., Moszczynska, A., Blusztajn, J.K., Shervin, A., Lozano, A. and Kish, S.J. (1997). Phospholipid biosynthetic enzymes in human brain. Lipids 32, 351-358. Impact factor: 2.56. Citations: 55.

Role: Collection of majority of data and help with data analysis.

6. Ross, B. M., Moszczynska, A., Erlich, J., and Kish, S.J. (1998). Phospholipid-metabolising enzymes in Alzheimer’s disease: Increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J. Neurochem. 70, 786-793. Impact factor: 4.24. Citations: 91.

Role: Help with data collection and data analysis.

7. Ross, B. M., Moszczynska, A., Erlich, J. and Kish, S.J. (1998). Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: Possible implications for Parkinson's disease. Neuroscience 83, 791-798. Impact factor: 3.33. Citations: 27.

Role: Collection of majority of the data and help with data analysis.

8. Moszczynska, A., Turenne, S., and Kish, S.J. (1998). Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine. Neurosci. Lett. 255, 49-52. Impact factor: 2.06. Citations: 37.

Role: Shared conceptual design of the study, experimental design, data collection and data analysis, shared decision to publish, participation in preparation (writing, figures, etc.) of the manuscript.

9. Ross, B. M., Turenne, S., Moszczynska, A., Warsh, J.J., and Kish, S.J. (1999). Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Res. 821, 407-413. Impact factor: 2.83. Citations: 131.

Role: Help with data collection and data analysis.

10. Ross, B.M., Eder, K., Moszczynska, A., Mamalias, N., Lamarche, J., Ang, L., Pandolfo, M., Rouleau, G., Kirchgessner, M., and Kish, S.J. (2000). Abnormal activity of membrane phospholipid synthetic enzymes in the brain of patients with Friedreich’s ataxia and spinocerebellar atrophy type-1. Mov. Disord. 15, 294-300. Impact factor: 5.63. Citations: 14.

Role: Collection of majority of the data and help with data analysis.

11. Worsley, J.N., Moszczynska, A., Falardeau, P., Kalasinsky, K.S., Schmunk, G., Guttman, M., Furukawa, Y., Ang, L., Adams, V., Reiber, G., Anthony, R.A., Wickham, D., and Kish, S.J. (2000). Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol. Psychiatry 5, 664-672. Impact factor: 15.15. Citations: 43.

Role: Help with data collection and data analysis.

12. Ross, B.M., Mamalias, N., Moszczynska, A., Rajput, A.H., and Kish, S.J. (2001). Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson’s disease. Neuroscience 102, 899-904. Impact factor: 3.33. Citations: 38.

Role: Help with data collection and data analysis.

13. Ross, B. M., Moszczynska, A., Perretti, F.J., Adams, V., Schmunk, G., Kalasinsky, K.S., Ang, L., Mamalias, N., Turenne, S., and Kish, S.J. (2002). Decreased activity of phospholipid metabolic enzymes in brain of human chronic users of cocaine and methamphetamine. Drug Alcohol Depend. 67, 73-79. Impact factor: 3.28. Citations: 24.

Role: Collection of majority of the data and help with data analysis.

14. Moszczynska, A., Fitzmaurice, P., Ang, L., Kalasinsky, K.S., Schmunk, G.A., Peretti, F.J., Aiken, S.S., Wickham, D.J., and Kish, S.J. (2004). Why is Parkinsonism not a feature of human methamphetamine users? Brain 127, 363-370. Impact factor: 10.23. Citations: 108.

Role: Shared conceptual design of the study, experimental design, data collection and data analysis, shared decision to publish, participation in preparation (writing, figures, etc.) and submission of the manuscript.

15. Mirecki (Moszczynska), A., Fitzmaurice, P., Ang, L., Kalasinsky, K.S., Peretti, F.J., Aiken, S.S., Wickham, D.J., Sherwin, A., Nobrega, J.N., Forman, H.J., and Kish, S.J. Brain antioxidant systems in chronic methamphetamine users. (2004). J. Neurochem. 89, 1396-1408. Impact factor: 4.24. Citations: 47.

Role: Conceptual design of the study, experimental design, data collection and data analysis, shared decision to publish, participation in preparation (writing, figures, etc.) and submission of the manuscript.

16. Pei, L., Lee, F.J.S., Moszczynska, A., Vukusic, B., and Liu, F. (2004). Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J. Neurosci. 24, 1149-1158. Impact factor: 6.91. Citations: 140.

Role: Participation in data collection, data analysis, and preparation of the manuscript.

17. *Lee, F.J.S., *Pei, L., *Moszczynska, A., Vukusic, B., Fletcher, P.J., and Liu, F. (2007). Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J. 26, 2127-2136. (* these authors contributed equally). Impact factor: 10.75. Citations: 113.

Role: Participation in conceptual design of the study and experimental design, data collection and data analysis, participation in preparation and submission of the manuscript.

18. Moszczynska, A., Saleh, J., Zhang H., Vukusic B, Lee F.J. and Liu, F. (2007). Parkin disrupts the α-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. J. Mol. Neurosci. 32, 217-227. Impact factor: 2.37. Citations: 30.

Role: Participation in conceptual design of the study and experimental design, data collection and data analysis, participation in preparation and submission of the manuscript.

19. Civetta A., Glass, S., Moszczynska, A., and Crease, T.J. (2008). The effect of transposon Pokey insertions on sequence variation in the 28S rRNA gene of Daphnia pulex. Genome 51, 988-1000. Impact factor: 1.65. Citations: 10.

Role: Participation in conceptual design of the study and experimental design, data collection and data analysis, participation in preparation and submission of the manuscript.

20. Moszczynska A., Locke, S., McLaughlin, D., Marcogliese D.J. and Crease, T.J. (2009). Development of primers for the mitochondrial cytochrome c oxidase I gene in digenetic trematodes (Platyhelminthes) illustrates the challenge of barcoding parasitic helminthes. Mol. Ecol. Res. 9 (Suppl. 1), 75–82. Impact factor: 7.43. Citations: 67.

Role: Participation in conceptual design of the study and experimental design, data collection and data analysis, participation in preparation and submission of the manuscript.

21. Yamamoto, B.K., Moszczynska, A., and Gudelsky, G.A. Amphetamine Toxicities: Classical and Emerging Mechanisms. (2010). Ann NYAS 1187:101-121 (Invited Review). Impact factor: 4.34. Citations: 151.

Role: Literature search, conceptual design of the manuscript, shared decision to publish, manuscript writing and submission.

22. Moszczynska, A. and Yamamoto, B.K. Methamphetamine oxidatively damages parkin and decreases the activity of 26S proteasome in vivo. (2011). J. Neurochem. 116:1005-1017. Impact factor: 4.24. Citations: 19.

Role: Conceptual design of the study, experimental design, data collection and data analysis, shared decision to publish, preparation (writing, figures, etc.) and submission of the manuscript.

23. Liu, B and Moszczynska, A. “Overexpression of parkin in the nigrostriatal system might protect dopaminergic terminals from methamphetamine neurotoxicity via regulation of dopamine transporter”. (2012) In: Catecholamine Research in the 21st Century. Editor: Lee E. Eiden. Impact factor: N/A.

Role: Conceptual design of the study, experimental design, data collection and data analysis, preparation and submission

24. Liu, B., Traini, R., Killlinger, B. and Moszczynska, A. Overexpression of parkin in rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity. (2013). Exp. Neurol. 247:359-372. Impact factor: 4.65. Citations: 3.

Role: Conceptual design of the study, experimental design, supervision of data collection, data analysis, decision to publish, preparation (writing, figures, etc.) and submission of the manuscript.

25. Killinger, B., Shah, M. and Moszczynska, A. Co-administration of betulinic acid and methamphetamine causes toxicity to dopaminergic and serotonergic nerve terminals in the striatum of late adolescent rats. (2013) J. Neurochem. 128:764-75. Impact factor: 4.24. Citations: 1.

Role: Conceptual design of the study, experimental design, supervision of data collection, major role in data analysis, decision to publish, preparation (writing, figures etc.) and submission of the manuscript.

26. Chauhan, C., Killinger, B., Miller, C. and Moszczynska, A. Single and binge methamphetamine administrations have different effects on the levels of dopamine D2 autoreceptor and dopamine transporter in rat striatum. (2014) Int. J. Mol. Sci. 5:5884-906. Feature Paper for Special Issue "G Protein-Coupled Receptor Signaling and Regulation". Impact factor: 2.24. Citations: 1.

Role: Conceptual design of the study, experimental design, supervision of data collection, data analysis, decision to publish, preparation (writing, figures, etc.) and submission of the manuscript.

27. Nadithe, V., Liu, R., Killinger, B.*, Movassaghian, S., Kim, N-H., Moszczynska, A., Masters, K., Gellman, S., and Merkel, O. “Screening of Nylon-3 Polymers, a New Class of Cationic Amphiphiles for siRNA Delivery" . (2014) Mol. Pharmaceutics. 12:362-74. Impact factor: 4.57. Citations: 1.

Role: Generating part of the data, manuscript revision.

28. Moszczynska, A. Methamphetamine and the Ubiquitin-Proteasome System (2015) Neuropathology of Addiction and Substance Misuse (ahead of print).

Role: Role: Conceptual design of the study, experimental design, supervision of data collection, data analysis, decision to publish, preparation (writing, figures, etc.) and submission of the manuscript.

29. Killinger, B.* and Moszczynska, A. Methamphetamine-induced alterations of microtubules in rat nigrostriatal dopamine pathway. (2015) J. Neurochem. (Impact factor: 4.24) (ahead of print).

Role: Conceptual design of the study, experimental design, supervision of data collection, supervision of data analysis, final data analysis, decision to publish, preparation (writing, figures, etc.) and submission of the manuscript.

30. Moszczynska, A., Flack, A., Ping, Q, Muotri, A. R. and Killinger, B.* Neurotoxic methamphetamine doses increase LINE-1 expression in the neurogenic zones of the adult rat brain. (2015) Sci. Reports. (Nature group) (Impact factor: 5.58) (ahead of print).

Role: Conceptual design of the study, experimental design, some data collection, data analysis, decision to publish, preparation (writing, figures, etc.) and submission of the manuscript.

 

Research Connect link

https://researchconnect.wayne.edu/en/persons/anna-moszczynska

Return to profile list